Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) announced management will participate in B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event at the InterContinental Boston.
On July 16, 2026, Neuronetics will join Compass Pathways in a panel on commercializing novel neuropsychiatric drugs and hold one-on-one investor meetings. No webcast is planned.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Leadership appointment | Neutral | -10.9% | Named a new Senior Vice President Sales with RSU inducement grant. |
| Jun 02 | Scientific meeting update | Neutral | -6.6% | Highlighted new real‑world NeuroStar TMS data at CTMSS 2026 meeting. |
| May 14 | Strategic collaboration | Positive | -13.9% | Announced collaboration to add neuronavigation to NeuroStar TMS platform. |
| May 05 | Earnings report | Positive | +7.4% | Reported Q1 2026 revenue growth and reiterated full‑year guidance ranges. |
| Apr 29 | Equity grants | Neutral | +14.1% | Disclosed inducement RSU grants to new non‑executive employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings, partnership, and governance headlines have generally seen the share price react in the same direction as the perceived tone of each event.
Regulatory & Risk Context
Reported data indicate high short positioning in the stock, which can increase the potential for sharp price swings in either direction if liquidity changes or sentiment shifts.
An effective S-3 resale shelf allows selling stockholders to register existing shares, with the filing stating the company will receive no proceeds, but concentrated resale activity could pressure the share price.
Key Terms
tms medical
neuropsychiatric medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that management will participate at the B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in-person at the InterContinental Boston.
Neuronetics will participate in a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs," alongside Compass Pathways, scheduled for Thursday, July 16, 2026. Management will also be available for one-on-one meetings with institutional investors throughout the day.
This is an in-person, invitation-only event, and there will be no live webcast of the panel discussion.
About Neuronetics
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
